Clinical trials: Drug Eluting Stents
Coronary Artery Disease
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
The ultimate goal of a paclitaxel eluting stent system (TAXUS stent) is to prevent restenosis by blunting the initial response to stent implant injury and sustaining the arrested response until vascular healing has taken place.
- Trial name
- NCT00292474
- Testing
- percutaneous coronary intervention
- Where
- United States
- Volunteers
- 1,326 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
- Trial name
- DestinACSion (NCT07190690)
- Testing
- ihtDEStiny® DES implanted, Xience™ DES implanted
- Where
- 20 sites in Spain
- Volunteers
- 2,100 people
- Sponsor
- Fundación EPIC
Coronary Artery Disease
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated.
- Trial name
- PRODIGY (NCT00611286)
- Testing
- clopidogrel treatment after bare metal stent implantation, clopidogrel after zotarolimus-eluting stent implantation, clopidogrel after paclitaxel-eluting stent implantation
- Where
- Italy
- Volunteers
- 1,700 people
- Sponsor
- Marco Valgimigli
Coronary Artery Disease
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES
To compare the efficacy and safety of clopidogrel monotherapy versus aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with DES.
- Trial name
- SMART-CHOICE (NCT02079194)
- Testing
- P2Y12 antagonist monotherapy, aspirin plus P2Y12 antagonist
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Evaluation of Effectiveness and Safety of the GENOUS STENT (IRIS-GENOUS STEMI)
The objective of this study is to evaluate effectiveness and safety of GENOUS EPC-coated stent in patients with STEMI with other drug-eluting stents (DESs).
- Trial name
- NCT01348373
- Where
- 16 sites in South Korea
- Volunteers
- 464 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease, Coronary Disease
Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI
The purpose of this study is to evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymer (SYNERGY™…
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Arterial Occlusive Diseases
- Trial name
- NCT02770651
- Testing
- Everolimus-Eluting stent, Zotarolimus-Eluting stent
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Keimyung University Dongsan Medical Center
Multivessel Coronary Artery Disease
Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP
The objective of the present study is to analyze the cost-effectiveness of percutaneous coronary intervention (PCI) using TAXUS stents compared to the costs of coronary artery bypass surgery (CABG) in patients with multivessel…
- Trial name
- NCT01199419
- Testing
- comparison of PCI vs. CABG in multivessel disease
- Where
- Austria
- Volunteers
- 207 people
- Sponsor
- Medical University of Vienna
Coronary Artery Disease
Comparison Between OFDI and IVUS in PCI Guidance for Biolimus A9 Eluting Stent Implantation
The aim of this study is to assess clinical safety and efficacy of percutaneous coronary intervention (PCI) using a newer generation drug-eluting stent (DES) in the context of optical frequency domain imaging (OFDI) guidance or…
- Trial name
- MISTIC-1 (NCT03292081)
- Testing
- OFDI, IVUS
- Where
- Japan
- Volunteers
- 96 people
- Sponsor
- Fujita Health University
Arterial Occlusive Diseases, Cardiovascular Diseases
IRIS-BVS AMI Registry
The purpose of this study is to evaluate the relative effectiveness and safety of Bioresorbable Vascular Scaffold in acute myocardial infarction compared to other (drug eluting stents) DES.
- Conditions
- Arterial Occlusive Diseases, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- IRIS BVS AMI (NCT02699671)
- Testing
- Bioresorbable Vascular Scaffold
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Duk-Woo Park, MD
Restenosis, Stable Angina Pectoris
Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4
The purpose of the study is to determine whether scoring balloon (SCB) plus paclitaxel-coated balloon (PCB) is superior to PCB alone for the treatment of restenosis within "limus"-eluting stents (LES)
- Conditions
- Restenosis, Stable Angina Pectoris, Acute Coronary Syndrome
- Trial name
- ISAR-DESIRE 4 (NCT01632371)
- Testing
- Paclitaxel Eluting Balloon + Scoring Balloon, Paclitaxel Eluting Balloon
- Where
- 2 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
Effectiveness of Clopidogrel Resinate in PCI(PRIDE)
This study is an open label, multi-center, randomized trial, which is designed to evaluate the efficacy and safety of clopidogrel derivative (Pregrel®) therapy for 12 months in patients undergoing PCI compared to conventional…
- Trial name
- NCT01349777
- Testing
- Pregrel®, Plavix®
- Where
- 3 sites in South Korea
- Volunteers
- 1,056 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease, Acute Coronary Syndrome
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy
Our first hypothesis is that dose adjustment of aspirin and clopidogrel based on biological monitoring reduces the rate of severe cardiovascular complications compared to a conventional strategy in patients scheduled for drug…
- Trial name
- ARCTIC (NCT00827411)
- Testing
- Aspirin and clopidogrel / Prasugrel, VerifyNow, Aspirin
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
AMI
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent
The trial aims to evaluate 12-month long-term efficiency of Excel stent in the treatment of coronary heart disease and inhibition of restenosis after coronary artery stenting as well as a 12 months' long-term safety after the…
- Trial name
- CREATE (NCT00331578)
- Testing
- Excel drug-eluting coronary artery stent
- Volunteers
- 2,077 people
- Sponsor
- JW Medical Systems Ltd
Coronary Artery Disease
BioFreedom Ultra Registry
Over the past three decades, coronary stent struts have been made progressively thinner. Thin strut drug-eluting stents (DES) performed better than their thicker counterparts in a recent study.
- Trial name
- NCT05094284
- Testing
- BioFreedom Ultra
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Chinese University of Hong Kong
Atherosclerosis, Heart Diseases, Coronary
A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)
EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care) trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm Coronary Stent System for the treatment of…
- Conditions
- Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03875651
- Testing
- SYNERGY 4.50 mm and 5.0 mm Coronary Stent System
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Heart Disease, Coronary Restenosis
Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
In a previous randomized comparison oral sirolimus plus bare metal stent compared to bare metal stent implantation alone demonstrated at one year of follow up a significant reduction of angiographic and clinical parameters of…
- Trial name
- ORAR III (NCT00552669)
- Testing
- Oral sirolimus, Drug Eluting stent
- Where
- 3 sites in Argentina
- Volunteers
- 200 people
- Sponsor
- Centro de estudios en Cardiologia Intervencionista
Acute Coronary Syndrome
Index of Microcirculatory Resistance After Drug-Eluting Stent Implantation With High Dose Atorvastatin Loading
Pre-treatment with statins decreased the incidence of cardiac enzyme increase after percutaneous coronary intervention (PCI) and distal embolization suspected to cause post-PCI myocardial damage.
- Trial name
- RESIST-ACS (NCT01491256)
- Testing
- Pre-procedural High dose atorvastatin loading, No pre-procedural high-dose atorvastatin loading
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- The Korean Society of Circulation
Coronary Artery Disease
Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study)
The main objective of this study is to assess the safety and effectiveness of the Sirolimus eluting Cypher Select(TM) stent in reducing angiographic in-stent late loss in de novo native coronary lesions as compared to the…
- Trial name
- NCT00130546
- Testing
- Paclitaxel-eluting TAXUS(TM), Sirolimus eluting Cypher Select(TM)
- Where
- Germany
- Volunteers
- 112 people
- Sponsor
- University Hospital Freiburg
Atherosclerosis, Heart Diseases, Coronary
A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System
This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in…
- Conditions
- Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT04807439
- Testing
- SYNERGY XLV (Megatron) Coronary Stent System
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)
The purpose of this study is to examine the safety and effectiveness of coronary stenting with the Cilotax stent compared to the Xience Prime stent in the treatment of diabetic patients.
- Trial name
- NCT01515228
- Testing
- Xience Prime, Cilotax stent
- Where
- 9 sites in South Korea
- Volunteers
- 291 people
- Sponsor
- CHEOL WHAN LEE, MD, PhD.